ALB and malignant colon neoplasm: The study indicated that the modified albumin NPs targeted the drug-resistant colon cancer cells (HCT8/ADR) and their microenvironment via multiple nutrient transporters, such as SPARC and mannose receptors, and displayed higher uptake efficiency than the non-modified albumin NPs.